ADDED
See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Market for Registrant s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities 28 6.
Management s Discussion and Analysis of Financial Condition and Results of Operations 30 7A.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 84 9A.
These forward-looking statements may include, without limitation, statements regarding our financial position, business strategy and the plans and objectives of management for Cencora, Inc.
s (the Company, Cencora, we, us, and our ) future operations; future liabilities and other obligations; anticipated trends and prospects in the industries in which our business operates; new products, services and related strategies; and capital allocation, including share repurchases and dividends.
When used in this Annual Report on Form 10-K, words such as aim, anticipate, believe, can, continue, could, estimate, expect, intend, may, might, on track, opportunity, plan, possible, potential, predict, project, seek, should, strive, sustain, synergy, target, will, would and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Additional factors include those described in this Annual Report on Form 10-K, including under the captions Risk Factors, Management s Discussion and Analysis of Financial Condition and Results of Operations, and Business, in our subsequent quarterly reports on Form 10-Q, including under the captions Risk Factors and Management s Discussion and Analysis of Financial Condition and Results of Operations, and in our subsequent filings and reports made with the U.S.
BUSINESS As used herein, the terms Company, Cencora, we, us, or our refer to Cencora, Inc., a Delaware corporation.
References to fiscal 2025, fiscal 2024, and fiscal 2023 refer to the fiscal years ended September 30, 2025, 2024, and 2023, respectively.
REMOVED
See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities 28 6.
Management's Discussion and Analysis of Financial Condition and Results of Operations 30 7A.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 80 9A.
These forward-looking statements may include, without limitation, statements regarding our financial position, business strategy and the plans and objectives of management for our future operations; future liabilities and other obligations; anticipated trends and prospects in the industries in which our business operates; new products, services and related strategies; and capital allocation, including share repurchases and dividends.
When used in this Annual Report on Form 10-K, words such as "aim," "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "might," "on track," "opportunity," "plan," "possible," "potential," "predict," "project," "seek," "should," "strive," "sustain," "synergy," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Additional factors include those described in this Annual Report on Form 10-K, including under the captions "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Business," in our subsequent quarterly reports on Form 10-Q, including under the captions "Risk Factors" and Management's Discussion and Analysis of Financial Condition and Results of Operations," and in our subsequent filings and reports made with the Securities and Exchange Commission.
BUSINESS As used herein, the terms "Company," "Cencora," "we," "us," or "our" refer to Cencora, Inc., a Delaware corporation.
References to "fiscal 2024," "fiscal 2023," and "fiscal 2022" refer to the fiscal years ended September 30, 2024, 2023, and 2022, respectively.
Industry Overview Pharmaceutical sales in the United States, as recently estimated by IQVIA, an independent third-party provider of information to the pharmaceutical and healthcare industry, are expected to grow at a compound annual growth rate of approximat ely 8.2% from 2023 through 2028, an d the growth rate is dependent, in part, on pharmaceutical manufacturer price increases.